PULM - Pulmatrix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Pulmatrix, Inc.

99 Hayden Avenue
Suite 390
Lexington, MA 02421
United States
781-357-2333
http://pulmatrix.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Mr. Teofilo David RaadPres, CEO & Director472.55kN/A1970
Mr. William E. Duke Jr.CFO, Treasurer & Sec.465.12kN/A1972
Dr. Robert S. Langer Jr.Founder & Member of Scientific Advisory BoardN/AN/A1949
Prof. David A. EdwardsFounder & Member of Scientific Advisory BoardN/AN/A1961
Dr. Alexander M. KlibanovFounderN/AN/A1950
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Pulmatrix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.